Search results
Results from the WOW.Com Content Network
Lobular carcinoma in situ (LCIS) is an incidental microscopic finding with characteristic cellular morphology and multifocal tissue patterns. The condition is a laboratory diagnosis and refers to unusual cells in the lobules of the breast . [ 1 ]
Stage 0 is a pre-cancerous or marker condition, either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Stages 1–3 are within the breast or regional lymph nodes. Stage 4 is a metastatic cancer. Metastatic breast cancer has a less favorable prognosis. Receptor status.
Lobular carcinoma is a form of tumor which primarily affects the lobules of a gland. It is sometimes considered equivalent to "terminal duct carcinoma". [1] If not otherwise specified, it generally refers to breast cancer. Examples include: Lobular carcinoma in situ; Invasive lobular carcinoma
Histopathologic types of breast cancer, with relative incidences and prognoses, with "invasive lobular carcinoma" at top right. Invasive lobular carcinoma (ILC) is breast cancer arising from the lobules of the mammary glands. [1] It accounts for 5–10% of invasive breast cancer. [2] [3] Rare cases of this carcinoma have been diagnosed in men ...
Lobular carcinoma in situ (in the mammary lobes) rarely causes a noticeable lump, and is often found incidentally during a biopsy for another reason. It is commonly spread throughout both breasts. Those with lobular carcinoma in situ also have an increased risk of developing breast cancer – around 1% develop breast cancer each year.
The Nottingham prognostic index (NPI) is used to determine prognosis following surgery for breast cancer. [1] [2] Its value is calculated using three pathological criteria: the size of the tumour; the number of involved lymph nodes; and the grade of the tumour. [1] It is calculated to select patients for adjuvant treatment.
Carcinomas of mixed type will have a specialized pattern or lobular carcinoma in the majority (i.e. at least 50%) of the tumor and a non-specialized pattern in between 10 and 49% of the sample. Thus, such tumors will be called mixed invasive NST and special type or mixed invasive carcinoma NST and lobular carcinoma. [24]
M8520/3 Lobular carcinoma, NOS (C50._) Lobular adenocarcinoma; Infiltrating lobular carcinoma, NOS; M8521/3 Infiltrating ductular carcinoma (C50._) M8522/2 Intraductal carcinoma and lobular carcinoma in situ (C50._) M8522/3 Infiltrating duct and lobular carcinoma (C50._) Lobular and ductal carcinoma; Infiltrating duct and lobular carcinoma in ...